Cite
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study.
MLA
Shi, Yuankai, et al. “Tunlametinib (HL-085) plus Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors: An Open-Label, Single-Arm, Multicenter, Phase I Study.” Experimental Hematology & Oncology, vol. 13, no. 1, May 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s40164-024-00528-0.
APA
Shi, Y., Han, X., Zhao, Q., Zheng, Y., Chen, J., Yu, X., Fang, J., Liu, Y., Huang, D., Liu, T., Shen, H., Luo, S., Yu, H., Cao, Y., Zhang, X., & Hu, P. (2024). Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study. Experimental Hematology & Oncology, 13(1), 1–12. https://doi.org/10.1186/s40164-024-00528-0
Chicago
Shi, Yuankai, Xiaohong Han, Qian Zhao, YuLong Zheng, Jianhua Chen, Xinmin Yu, Jian Fang, et al. 2024. “Tunlametinib (HL-085) plus Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors: An Open-Label, Single-Arm, Multicenter, Phase I Study.” Experimental Hematology & Oncology 13 (1): 1–12. doi:10.1186/s40164-024-00528-0.